EMA has insisted that the concerns raised about its scientific advice given to pharmaceutical companies stem from a flawed understanding of the activities of the agency and its partners in this area.
The European Medicines Agency (EMA) has insisted that the concerns raised about its scientific advice given to pharmaceutical companies stem from a flawed understanding of the activities of the agency and its partners in this area.
A coalition of European medicines advocates, including Health Action International (HAI), has criticized the EMA for providing confidential advice to pharmaceutical companies in exchange for fees, to give them guidance on their development plans for new drugs. The coalition worried that the agency is attempting to extend this practice to national health technology assessment bodies in the European Union, according to a report published on July 15 by thepharmaletter.com.
In a statement sent to appliedclinicaltrialsonline.com, EMA says it welcomes all comments submitted by stakeholders about its public consultation on its best practice guidance for pilot parallel scientific advice procedures involving the EMA and health-technology-assessment (HTA) bodies.
“Scientific advice is an important tool used by the EMA, EU Member States and other international regulators to facilitate the development and availability of high-quality, effective and acceptably safe medicines, for the benefit of patients,” noted the agency. “Scientific advice helps the company to make sure that it performs the appropriate tests and studies, so that no major objections regarding the design of the tests are likely to be raised during evaluation of the marketing-authorization application.”
EMA concedes that seeking and following scientific advice increases the probability of a positive outcome for a marketing application, but says it is not always the case. Scientific advice is prospective in nature; it focuses on development strategies rather than pre-evaluation of data to support a marketing-authorization application, and it is not legally binding on the agency or on the sponsor, continued the statement.
“Scientific advice is also a valuable instrument to support SMEs, as well as to assist in the development of new medicines for orphan (rare) diseases, pediatric medicines and advanced therapy medicinal products. For these categories, reduced scientific advice fees apply,” explained the agency.
Also, some new medicines authorized by the European Commission based on the EMA’s scientific opinions fail to be reimbursed and/or used as expected because they fail to match the requirements of HTA bodies. “Therefore there is a clear need to initiate early dialogue between medicines developers, the EMA and HTA bodies to discuss and agree on a development plan that generates data that both parties can use to determine a medicine's benefit-risk balance and value. This strong interaction is critical to enable innovation to reach patients, and ultimately for the benefit of public health,” noted the statement.
Regulation 726/2004 foresees that the agency must provide scientific advice to companies, and in fact the Scientific Advice Working Party is mandated in the legislation. This working party includes patient representatives for its procedures.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.